Azienda Ospedaliera-Universitaria Di Cosenza
- Address
- Via Felice Migliori 1, 87100 Cosenza, Italy
Azienda Ospedaliera-Universitaria Di Cosenza
The Azienda Ospedaliera-Universitaria Di Cosenza is a comprehensive academic medical center actively engaged in advanced clinical research across multiple therapeutic areas. The institution demonstrates particular expertise in hematologic malignancies and cancer-related complications, with a strong focus on innovative treatment approaches and therapeutic optimization.
- Multiple myeloma research, including novel maintenance therapies post-transplantation and combination regimens with teclistamab, carfilzomib, and lenalidomide
- Cancer-associated venous thromboembolism, investigating anticoagulation strategies for patients with solid tumors and hematologic cancers
- Pediatric and adult hematologic malignancies, including Philadelphia chromosome-positive acute lymphoblastic leukemia and rhabdomyosarcoma
- Chronic kidney disease management through adaptive platform trials
The center's research portfolio reflects a commitment to both precision oncology and supportive care, participating in international multicenter trials that address critical gaps in cancer treatment. Their involvement in studies ranging from frontline chemotherapy optimization to relapsed disease management, alongside investigations into autologous stem cell transplantation protocols, positions the institution as a key contributor to advancing standards of care in oncology and hematology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 55 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Novo Nordisk A/S1active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera-Universitaria Di Cosenza
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 55 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 3 | Unknown | 2017-10-02 | 2024-12-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.